Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

High-Dose Cyclophosphamide for hard-to-treat patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, a phase II result.

Michot JM, Annereau M, Danu A, Legoupil C, Bertin L, Chahine C, Achab N, Antosikova A, Cerutti A, Rossignol J, Ghez D, Willekens C, Dartigues P, Lazarovici J, Lemare F, Ribrag V.

Eur J Haematol. 2019 Dec 14. doi: 10.1111/ejh.13369. [Epub ahead of print]

PMID:
31838764
2.

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.

Blez D, Blaize M, Soussain C, Boissonnas A, Meghraoui-Kheddar A, Menezes N, Portalier A, Combadière C, Leblond V, Ghez D, Fekkar A.

Haematologica. 2019 Jun 6. pii: haematol.2019.219220. doi: 10.3324/haematol.2019.219220. [Epub ahead of print]

3.

Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.

Quinquenel A, Godet S, Dartigeas C, Ysebaert L, Dupuis J, Ohanyan H, Collignon A, Gilardin L, Lepretre S, Dilhuydy MS, Vignon M, de Guibert S, Dmytruk N, Durot E, Ghez D, Roos Weil D, Béné MC, Toussaint E, Merabet F, Lévy V, Delmer A, Aurran T.

Am J Hematol. 2019 Jul;94(7):E183-E185. doi: 10.1002/ajh.25480. Epub 2019 Apr 11. No abstract available.

PMID:
30945328
4.

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

Assi T, Danu A, Mateus C, Robert C, Michot JM, Ibrahim T, Lazarovici J, Ghez D, Rossignol J, Dartigues P, Terroir-Cassou-Mounat M, Ribrag V.

Immunotherapy. 2019 May;11(7):591-598. doi: 10.2217/imt-2018-0169.

PMID:
30943861
5.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.

Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H.

Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.

PMID:
30890552
6.

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.

Micol JB, Pilorge S, Ghez D.

N Engl J Med. 2019 Feb 14;380(7):696. doi: 10.1056/NEJMc1814963. No abstract available.

PMID:
30785715
7.

Ibrutinib-Induced Neutrophilic Dermatosis.

El Halabi L, Cherif-Rebai K, Michot JM, Ghez D.

Am J Dermatopathol. 2018 Mar;40(3):198-200. doi: 10.1097/DAD.0000000000000862.

PMID:
29473834
8.

Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?

Lazarovici J, Terroir-Cassou-Mounat M, Ghez D.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):884-885. doi: 10.1007/s00259-018-3949-8. No abstract available.

PMID:
29453703
9.

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.

Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group.

Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1.

PMID:
29437588
10.

[Hodgkin lymphoma: Current and future therapeutic strategies].

Turpin A, Michot JM, Kempf E, Mazeron R, Dartigues P, Terroir M, Boros A, Bonnetier S, Castilla-Llorente C, Coman T, Danu A, Ghez D, Pilorge S, Arfi-Rouche J, Dercle L, Soria JC, Carde P, Ribrag V, Fermé C, Lazarovici J.

Bull Cancer. 2018 Jan;105(1):81-98. doi: 10.1016/j.bulcan.2017.11.008. Epub 2017 Dec 27. Review. French.

PMID:
29289336
11.

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Ruggiu M, Oberkampf F, Ghez D, Cony-Makhoul P, Beckeriche F, Cano I, Taksin AL, Benbrahim O, Ghez S, Farhat H, Rigaudeau S, de Gunzburg N, Lara D, Terre C, Raggueneau V, Garcia I, Spentchian M, De Botton S, Rousselot P.

Leuk Lymphoma. 2018 Jul;59(7):1659-1665. doi: 10.1080/10428194.2017.1397666. Epub 2017 Nov 28.

PMID:
29179634
12.

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.

Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, Ghez D, Lazarovici J, Michot JM, Khalife-Saleh N, Lapierre V, Alenxandrova K, Arfi-Rouche J, Bourhis JH, Ribrag V.

Leuk Lymphoma. 2018 Nov;59(11):2580-2587. doi: 10.1080/10428194.2017.1403019. Epub 2017 Nov 22.

PMID:
29164977
13.

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A.

Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. No abstract available.

14.

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S.

Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Review.

PMID:
28892775
15.

Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

Lazarovici J, Terroir M, Arfi-Rouche J, Michot JM, Mussot S, Florea V, Ghigna MR, Dartigues P, Petrovanu C, Danu A, Fermé C, Ribrag V, Ghez D.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2018-2024. doi: 10.1007/s00259-017-3758-5. Epub 2017 Jun 21.

PMID:
28634685
16.

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.

Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V.

Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9.

PMID:
28597151
17.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

18.

The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation.

Routy B, Letendre C, Enot D, Chénard-Poirier M, Mehraj V, Séguin NC, Guenda K, Gagnon K, Woerther PL, Ghez D, Lachance S.

Oncoimmunology. 2016 Dec 27;6(1):e1258506. doi: 10.1080/2162402X.2016.1258506. eCollection 2017.

19.

Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.

Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, Danu A, Bermudez E, Lazarovici J, Ghez D, Leary A, Pistilli B, Lemare F, Solary E, de Botton S, Desmaris RP, Micol JB.

Leuk Res. 2017 Apr;55:58-64. doi: 10.1016/j.leukres.2017.01.024. Epub 2017 Jan 20.

PMID:
28131982
20.

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.

Ghez D, Fortpied C, Mounier N, Carde P, Perrot A, Khaled H, Amorim S, Ramadan S, Bras FL, Erlanson M, Herbaux C, Marolleau JP, Nicolas-Virelezier E, Casasnovas O, Stamatoullas-Bastard A, Fermé C.

Bone Marrow Transplant. 2017 Feb;52(2):310-312. doi: 10.1038/bmt.2016.271. Epub 2016 Nov 28. No abstract available.

PMID:
27892946
21.

An uncommon cause of dysuria solved by "boom-boom" radiotherapy.

Mazeron R, Bosq J, Rivin del Campo E, Arfi-Rouche J, Boros A, Ghez D.

Cancer Radiother. 2016 Apr;20(2):115-8. doi: 10.1016/j.canrad.2015.12.001. Epub 2016 Mar 9.

PMID:
26971221
22.

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P.

Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31.

23.

Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?

El Halabi L, Ghez D, Ribrag V.

Expert Rev Hematol. 2016 Mar;9(3):271-81. doi: 10.1586/17474086.2016.1134309. Epub 2016 Jan 18. Review.

PMID:
26689790
24.

Investigational drugs for T-cell lymphoma.

Ghez D, Danu A, Ribrag V.

Expert Opin Investig Drugs. 2016;25(2):171-81. doi: 10.1517/13543784.2016.1121994. Epub 2015 Dec 17. Review.

PMID:
26576861
25.

Adult T-Cell Leukemia/Lymphoma in a Caucasian Patient After Sexual Transmission of Human T-Cell Lymphotropic Virus Type 1.

Sibon D, Cassar O, Duga I, Brouzes C, Ghez D, Pasquier C, Sibon C, Desrames A, Mortreux F, Wattel E, Bazarbachi A, Gessain A, Hermine O.

Open Forum Infect Dis. 2015 Mar 6;2(2):ofv032. doi: 10.1093/ofid/ofv032. eCollection 2015 Apr.

26.

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V.

Eur J Cancer. 2015 Nov;51(16):2386-95. doi: 10.1016/j.ejca.2015.07.009. Epub 2015 Aug 5.

PMID:
26254810
27.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology.

Ann Hematol. 2014 Dec;93(12):1977-83. doi: 10.1007/s00277-014-2140-y. Epub 2014 Jul 5.

28.

Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?

Micol JB, Chahine C, Woerther PL, Ghez D, Netzer F, Dufour C, Merad M, Blot F, Chachaty E, de Botton S, Gachot B.

Clin Microbiol Infect. 2014 Jul;20(7):O453-5. doi: 10.1111/1469-0691.12445. Epub 2013 Dec 9.

29.

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.

Ghez D, Micol JB, Pasquier F, Auger N, Saada V, Spentchian M, Ianotto JC, Bourhis JH, Bennaceur-Griscelli A, Terré C, Castaigne S, Rigaudeau S, Rousselot P, de Botton S.

Eur J Cancer. 2013 Nov;49(17):3666-70. doi: 10.1016/j.ejca.2013.07.147. Epub 2013 Aug 19.

PMID:
23968731
30.

[A retroperitoneal fibrosis in a 38-year-old Egyptian man].

Danu A, Chalumeau L, Ribrag V, de Botton S, Said Mahmmod S, Blot F, Ghez D, Chalumeau N, Bienvenu B.

Rev Med Interne. 2013 Jan;34(1):57-60. doi: 10.1016/j.revmed.2012.07.002. Epub 2012 Dec 8. French. No abstract available.

PMID:
23228883
31.

Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.

Crickx E, Wittnebel S, Pasquier F, Danu A, Bourhis JH, Ribrag V, Boué F, Miceli C, Mariette X, Moreau P, Botton Sd, Ghez D.

Eur J Cancer. 2013 Jan;49(2):411-5. doi: 10.1016/j.ejca.2012.08.009. Epub 2012 Sep 12.

PMID:
22980726
32.

Clinical and biological features of t(4;14) multiple myeloma: a prospective study.

Karlin L, Soulier J, Chandesris O, Choquet S, Belhadj K, Macro M, Bouscary D, Porcher R, Ghez D, Malphettes M, Asli B, Brouet JC, Bories JC, Hermine O, Fermand JP, Arnulf B.

Leuk Lymphoma. 2011 Feb;52(2):238-46. doi: 10.3109/10428194.2010.537795. Epub 2011 Jan 24.

PMID:
21261498
33.

Current concepts regarding the HTLV-1 receptor complex.

Ghez D, Lepelletier Y, Jones KS, Pique C, Hermine O.

Retrovirology. 2010 Nov 29;7:99. doi: 10.1186/1742-4690-7-99. Review.

34.

Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin.

Suarez F, Olivier G, Garcia-Hermoso D, Randriamalala E, Ghez D, Bruneau J, Kauffmann-Lacroix C, Bougnoux ME, Lortholary O.

J Clin Microbiol. 2011 Jan;49(1):461-5. doi: 10.1128/JCM.01213-10. Epub 2010 Nov 10.

35.

Rapamycin for refractory acute graft-versus-host disease.

Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, Deau-Fischer B, Varet B, Hermine O, Buzyn A.

Transplantation. 2009 Nov 15;88(9):1081-7. doi: 10.1097/TP.0b013e3181ba0a13.

PMID:
19898203
36.

Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation.

Ghez D, Renand A, Lepelletier Y, Sibon D, Suarez F, Rubio MT, Delarue R, Buzyn A, Beljord K, Tanaka Y, Varet B, Hermine O.

J Clin Virol. 2009 Dec;46(4):378-80. doi: 10.1016/j.jcv.2009.07.020.

PMID:
19836302
37.

[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].

Willems L, Suarez F, Messas E, Baubion N, Decaudin D, Fourquet A, Ghez D, Delarue R, Hermine O, Buzyn A, Varet B, Rubio MT.

Bull Cancer. 2010 Feb;97(2):245-54. doi: 10.1684/bdc.2009.0958. French.

38.

High risk of cardiac dysfunction after treatment of secondary acute myeloid leukaemia to breast cancer.

Willems L, Suarez F, Baubion N, Decaudin D, Ghez D, Hermine O, Varet B, Rubio MT.

Ann Oncol. 2009 Mar;20(3):597-9. doi: 10.1093/annonc/mdn776. Epub 2009 Jan 27. No abstract available.

PMID:
19174451
39.

Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?

Chandesris MO, Ghez D, Besson C, Suarez F, Delarue R, Rubio MT, Bazarbachi A, Varet B, Hermine O.

BMJ Case Rep. 2009;2009. pii: bcr01.2009.1449. doi: 10.1136/bcr.01.2009.1449. Epub 2009 Aug 10.

40.

Thalidomide-induced pneumonitis.

Wyplosz B, Lerolle U, Israël-Biet D, Dougados J, Lillo-Le Louët A, Ghez D, Pouchot J.

Eur J Intern Med. 2008 Nov;19(7):e57-8. doi: 10.1016/j.ejim.2008.02.004. Epub 2008 Apr 18. No abstract available.

PMID:
19013366
41.

Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance.

Suarez F, Lortholary O, Buland S, Rubio MT, Ghez D, Mahé V, Quesne G, Poirée S, Buzyn A, Varet B, Berche P, Bougnoux ME.

J Clin Microbiol. 2008 Nov;46(11):3772-7. doi: 10.1128/JCM.01086-08. Epub 2008 Sep 24.

42.

Case-control cohort study of patients' perceptions of disability in mastocytosis.

Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A.

PLoS One. 2008 May 28;3(5):e2266. doi: 10.1371/journal.pone.0002266.

43.

MLL insertion with MLL-MLLT3 gene fusion in acute leukemia: case report and review of the literature.

Soler G, Radford I, Meyer C, Marschalek R, Brouzes C, Ghez D, Romana S, Berger R.

Cancer Genet Cytogenet. 2008 May;183(1):53-9. doi: 10.1016/j.cancergencyto.2008.01.016. Review.

PMID:
18474298
44.

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.

Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, Zermati Y, Barète S, Sans B, Baude C, Ghez D, Suarez F, Delarue R, Casassus P, Bodemer C, Catteau A, Soppelsa F, Hanssens K, Arock M, Sobol H, Fraitag S, Canioni D, Moussy A, Launay JM, Dubreuil P, Hermine O, Lortholary O; AFIRMM network.

PLoS One. 2008 Apr 9;3(4):e1906. doi: 10.1371/journal.pone.0001906.

45.

Thalidomide in advanced mastocytosis.

Damaj G, Bernit E, Ghez D, Claisse JF, Schleinitz N, Harlé JR, Canioni D, Hermine O.

Br J Haematol. 2008 Apr;141(2):249-53. doi: 10.1111/j.1365-2141.2008.07038.x. Epub 2008 Feb 26.

PMID:
18307561
46.

Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody.

Callens C, Moura IC, Lepelletier Y, Coulon S, Renand A, Dussiot M, Ghez D, Benhamou M, Monteiro RC, Bazarbachi A, Hermine O.

Leukemia. 2008 Jan;22(1):42-8. Epub 2007 Sep 27. Review.

PMID:
17898788
47.

Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis.

Lefrère F, Zohar S, Beaudier S, Audat F, Ribeil JA, Ghez D, Varet B, Cavazzana-Calvo M, Dal Cortivo L, Letestu R, McIntyre E, Brouzes C.

Transfusion. 2007 Oct;47(10):1851-7.

PMID:
17880611
48.

Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome.

Wallet N, Ghez D, Delarue R, Suarez F, Rubio MT, Fischer A, Canioni D, Varet B, Hermine O.

Clin Lymphoma Myeloma. 2007 May;7(6):425-7.

PMID:
17621409
49.

Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.

Ghez D, Lepelletier Y, Lambert S, Fourneau JM, Blot V, Janvier S, Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O.

J Virol. 2006 Jul;80(14):6844-54.

50.

Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma.

Ghez D, Damotte D, Perrine SP, Faller DV, Canioni D, Brousse N, Lefrère F, Varet B, Hermine O.

Clin Lymphoma Myeloma. 2006 Mar;6(5):417-9.

PMID:
16640822

Supplemental Content

Support Center